Companion Animal Therapeutics - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511241442

Publication Date:

November 11, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Companion Animal Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from 拢2.6bn in 2015 to 拢4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about 楼67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 22%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Companion Animal Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Companion Animal Therapeutics by region & country, by Type, and by Application.
The Companion Animal Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Animal Therapeutics.
麻豆原创 Segmentation
By Company
Aratana Therapeutics
Elanco
Boehringer Ingelheim GmbH
Ceva Sante Animale
Dechra Pharmaceuticals
Eli Lilly and Company
Merck
Vetoquinol
Zoetis
Segment by Type:
Infectious Diseases
Dermatological Diseases
Orthopedic Diseases
Behavioral Disorders
Others
Segment by Application
Dogs
Cats
Horses
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Companion Animal Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Companion Animal Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Companion Animal Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Companion Animal Therapeutics Product Introduction
1.2 Global Companion Animal Therapeutics 麻豆原创 Size Forecast
1.3 Companion Animal Therapeutics 麻豆原创 Trends & Drivers
1.3.1 Companion Animal Therapeutics Industry Trends
1.3.2 Companion Animal Therapeutics 麻豆原创 Drivers & Opportunity
1.3.3 Companion Animal Therapeutics 麻豆原创 Challenges
1.3.4 Companion Animal Therapeutics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Companion Animal Therapeutics Players Revenue Ranking (2023)
2.2 Global Companion Animal Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Companion Animal Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Companion Animal Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Companion Animal Therapeutics
2.6 Companion Animal Therapeutics 麻豆原创 Competitive Analysis
2.6.1 Companion Animal Therapeutics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Companion Animal Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Animal Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Infectious Diseases
3.1.2 Dermatological Diseases
3.1.3 Orthopedic Diseases
3.1.4 Behavioral Disorders
3.1.5 Others
3.2 Global Companion Animal Therapeutics Sales Value by Type
3.2.1 Global Companion Animal Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Companion Animal Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Companion Animal Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Dogs
4.1.2 Cats
4.1.3 Horses
4.1.4 Other
4.2 Global Companion Animal Therapeutics Sales Value by Application
4.2.1 Global Companion Animal Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Companion Animal Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Companion Animal Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Companion Animal Therapeutics Sales Value by Region
5.1.1 Global Companion Animal Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Companion Animal Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Companion Animal Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Companion Animal Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Companion Animal Therapeutics Sales Value, 2019-2030
5.2.2 North America Companion Animal Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Companion Animal Therapeutics Sales Value, 2019-2030
5.3.2 Europe Companion Animal Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Companion Animal Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Companion Animal Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Companion Animal Therapeutics Sales Value, 2019-2030
5.5.2 South America Companion Animal Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Companion Animal Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Companion Animal Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Companion Animal Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Companion Animal Therapeutics Sales Value
6.3 United States
6.3.1 United States Companion Animal Therapeutics Sales Value, 2019-2030
6.3.2 United States Companion Animal Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Companion Animal Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Companion Animal Therapeutics Sales Value, 2019-2030
6.4.2 Europe Companion Animal Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Companion Animal Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Companion Animal Therapeutics Sales Value, 2019-2030
6.5.2 China Companion Animal Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Companion Animal Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Companion Animal Therapeutics Sales Value, 2019-2030
6.6.2 Japan Companion Animal Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Companion Animal Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Companion Animal Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Companion Animal Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Companion Animal Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Companion Animal Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Companion Animal Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Companion Animal Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Companion Animal Therapeutics Sales Value, 2019-2030
6.9.2 India Companion Animal Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Companion Animal Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Aratana Therapeutics
7.1.1 Aratana Therapeutics Profile
7.1.2 Aratana Therapeutics Main Business
7.1.3 Aratana Therapeutics Companion Animal Therapeutics Products, Services and Solutions
7.1.4 Aratana Therapeutics Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 Aratana Therapeutics Recent Developments
7.2 Elanco
7.2.1 Elanco Profile
7.2.2 Elanco Main Business
7.2.3 Elanco Companion Animal Therapeutics Products, Services and Solutions
7.2.4 Elanco Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 Elanco Recent Developments
7.3 Boehringer Ingelheim GmbH
7.3.1 Boehringer Ingelheim GmbH Profile
7.3.2 Boehringer Ingelheim GmbH Main Business
7.3.3 Boehringer Ingelheim GmbH Companion Animal Therapeutics Products, Services and Solutions
7.3.4 Boehringer Ingelheim GmbH Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Ceva Sante Animale Recent Developments
7.4 Ceva Sante Animale
7.4.1 Ceva Sante Animale Profile
7.4.2 Ceva Sante Animale Main Business
7.4.3 Ceva Sante Animale Companion Animal Therapeutics Products, Services and Solutions
7.4.4 Ceva Sante Animale Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Ceva Sante Animale Recent Developments
7.5 Dechra Pharmaceuticals
7.5.1 Dechra Pharmaceuticals Profile
7.5.2 Dechra Pharmaceuticals Main Business
7.5.3 Dechra Pharmaceuticals Companion Animal Therapeutics Products, Services and Solutions
7.5.4 Dechra Pharmaceuticals Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 Dechra Pharmaceuticals Recent Developments
7.6 Eli Lilly and Company
7.6.1 Eli Lilly and Company Profile
7.6.2 Eli Lilly and Company Main Business
7.6.3 Eli Lilly and Company Companion Animal Therapeutics Products, Services and Solutions
7.6.4 Eli Lilly and Company Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Eli Lilly and Company Recent Developments
7.7 Merck
7.7.1 Merck Profile
7.7.2 Merck Main Business
7.7.3 Merck Companion Animal Therapeutics Products, Services and Solutions
7.7.4 Merck Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Merck Recent Developments
7.8 Vetoquinol
7.8.1 Vetoquinol Profile
7.8.2 Vetoquinol Main Business
7.8.3 Vetoquinol Companion Animal Therapeutics Products, Services and Solutions
7.8.4 Vetoquinol Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Vetoquinol Recent Developments
7.9 Zoetis
7.9.1 Zoetis Profile
7.9.2 Zoetis Main Business
7.9.3 Zoetis Companion Animal Therapeutics Products, Services and Solutions
7.9.4 Zoetis Companion Animal Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 Zoetis Recent Developments
8 Industry Chain Analysis
8.1 Companion Animal Therapeutics Industrial Chain
8.2 Companion Animal Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Companion Animal Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Companion Animal Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Aratana Therapeutics
Elanco
Boehringer Ingelheim GmbH
Ceva Sante Animale
Dechra Pharmaceuticals
Eli Lilly and Company
Merck
Vetoquinol
Zoetis

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.